Nano-Wrapped Vancomycin Derivative Can Be Taken Orally and Still Fight Systemic Infections in Mice | Research

The takeaway

A liposomal nanocarrier with cell-penetrating peptides enabled oral delivery of the vancomycin derivative FU002, achieving significant therapeutic efficacy against systemic bacterial infection in mice.

Oral efficacy in systemic infection
Liposomal FU002 delivered orally produced significant therapeutic benefit in a mouse model of systemic bacterial infection — achieving what free vancomycin derivatives cannot

What the researchers found

Liposomal FU002 coated with cyclic cell-penetrating peptides achieved oral bioavailability in rats and significant therapeutic efficacy against systemic infection in mice when administered orally, while maintaining antimicrobial activity in vitro and in vivo.

Why it matters

Turning injectable-only antibiotics into oral drugs would be transformative for healthcare — reducing hospitalizations, improving patient comfort, and expanding access in resource-limited settings. This proof-of-concept shows that nanotechnology can enable oral delivery of peptide antibiotics that were previously impossible to take by mouth.

The numbers in context

Surface-modified liposomes showed significantly improved oral bioavailability compared to unformulated FU002.

How the study worked

FU002 was incorporated into tetraether lipid-stabilized liposomes modified with cyclic cell-penetrating peptides. Caco-2 cell binding and cytotoxicity were assessed in vitro. Pharmacokinetics were studied in rats (oral vs. IV). Antimicrobial activity was tested in vitro and in a murine systemic infection model with oral dosing.

Who was studied

In vitro GI simulation and early animal testing

What this study cannot tell us

Early-stage preclinical study in rodents — oral bioavailability improvement was demonstrated but absolute values weren't detailed in the abstract. The complexity and cost of manufacturing liposomal formulations with cell-penetrating peptides may limit scalability. Long-term safety of the nanocarrier components is unknown. Human gut conditions may differ from rodent models.

How to read the evidence

Preliminary evidence from a preclinical proof-of-concept study in rodents. The results are promising but far from clinical application — human bioavailability, safety, and efficacy remain untested.

When this study was published

Published in 2024, representing cutting-edge nanotechnology approaches to one of pharmaceutical science's biggest challenges — oral delivery of peptide drugs.

The bigger picture

Antibiotic resistance is a growing global crisis, and many of the most potent antibiotics (including vancomycin derivatives) can only be given IV. Making these drugs orally bioavailable through nanocarrier technology could dramatically change how we treat serious infections — potentially enabling outpatient treatment of conditions that currently require hospitalization for IV antibiotics.

Questions still open

What is the absolute oral bioavailability of liposomal FU002 compared to IV administration?
Could this nanocarrier platform be adapted for other peptide antibiotics or antimicrobial peptides?
Is the manufacturing process scalable and cost-effective enough for clinical development?

Common questions

Why can't vancomycin normally be taken as a pill?

Vancomycin is a large, complex peptide molecule that gets destroyed by stomach acid and digestive enzymes, and even if it survives, it's too big and poorly absorbed to cross the intestinal wall into the bloodstream. When taken orally, it stays in the gut — useful for gut infections like C. diff, but useless for infections elsewhere in the body. That's why serious infections requiring vancomycin need IV administration in a hospital.

What are cell-penetrating peptides and how do they help?

Cell-penetrating peptides (CPPs) are short amino acid sequences that can cross cell membranes — essentially molecular keys that unlock the body's cellular barriers. By attaching CPPs to the surface of the drug-carrying liposomes, researchers gave them the ability to cross the intestinal wall and deliver their antibiotic cargo into the bloodstream. It's like adding a GPS and a pass card to a delivery truck so it can navigate through security checkpoints.

Read the original research

Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal Nanocarrier.

Advanced healthcare materials, 13(14), e2303654

View on PubMed ↗Publisher’s paper ↗

Citation

Werner, Julia; Umstätter, Florian; Hertlein, Tobias; Mühlberg, Eric; Beijer, Barbro; Wohlfart, Sabrina; Zimmermann, Stefan; Haberkorn, Uwe; Ohlsen, Knut; Fricker, Gert; Mier, Walter; Uhl, Philipp. (2024). Oral Delivery of the Vancomycin Derivative FU002 by a Surface-Modified Liposomal Nanocarrier.. Advanced healthcare materials, 13(14), e2303654. https://doi.org/10.1002/adhm.202303654